Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.

Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N.

Drug Metab Dispos. 2013 Dec;41(12):2056-65. doi: 10.1124/dmd.113.052639. Epub 2013 Jun 19.

2.

Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.

VandenBrink BM, Davis JA, Pearson JT, Foti RS, Wienkers LC, Rock DA.

Mol Pharmacol. 2012 Nov;82(5):835-42. doi: 10.1124/mol.112.080739. Epub 2012 Aug 2.

PMID:
22859722
3.

In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.

Dickmann LJ, VandenBrink BM, Lin YS.

Drug Metab Dispos. 2012 Jul;40(7):1263-7. doi: 10.1124/dmd.112.044909. Epub 2012 Apr 24.

PMID:
22531045
4.

Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.

Henne KR, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK.

Drug Metab Dispos. 2012 Jul;40(7):1429-40. doi: 10.1124/dmd.112.045708. Epub 2012 Apr 19.

PMID:
22517972
5.

Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2012 Jan;40(1):47-53. doi: 10.1124/dmd.111.041210. Epub 2011 Oct 5.

PMID:
21976621
6.

Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2011 Sep;39(9):1546-54. doi: 10.1124/dmd.111.039065. Epub 2011 Jun 22.

PMID:
21697463
7.

Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.

Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL.

Drug Metab Dispos. 2010 Jun;38(6):963-72. doi: 10.1124/dmd.110.032391. Epub 2010 Mar 3.

8.

The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

VandenBrink BM, Isoherranen N.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):66-77. Review.

Supplemental Content

Loading ...
Support Center